"[Mylan CEO Heather Bresch] should resign for price gouging rather than get a raise, but like so many of her fellow executives Bresch sails serenely on as her fellow Americans drown in health care debt. Her career and the success of her company epitomize everything that so enrages every voter who believes that the fix is in and that the system is weighted in favor of those with big money and serious connections... And even at half-price, the cost of an EpiPen remains an outrage. In fact, some estimate that the dose of epinephrine used in the injector may really cost as little as a dollar. In other words, this is one more, big old scam — yet another case of big business trying to pull the wool over the citizens’ eyes and pick our pockets while the government and our politicians mostly look the other way. The Mylan mess is the cozy relationship between regulators and the regulated in a nutshell. Throughout government, politics and business, cash contributions are made, connections are used, strings are pulled and favors are requested and returned. So the system wins again, corrupt as hell. But take notice. Realize that the rest of us are more and more aware of how we’re being had — and that we truly must be heard and heeded. Unless the tiny-hearted, gold-digging CEOs of America’s corporations and our leaders get the dollar signs out of their eyes and come to their senses, they are writing a prescription for an angry public response that not even their bought-and-paid-for Congress can hold at bay."
Issues and developments related to ethics, information, and technologies, examined in the ethics and intellectual property graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology" will be published in Summer 2025. Kip Currier, PhD, JD
Showing posts with label price gouging. Show all posts
Showing posts with label price gouging. Show all posts
Wednesday, August 31, 2016
Drugs And Privilege: Big Business, Congress And The EpiPen; Huffington Post, 8/31/16
Michael Winship, Huffington Post; Drugs And Privilege: Big Business, Congress And The EpiPen:
Sunday, December 20, 2015
Everything You Know About Martin Shkreli Is Wrong—or Is It?; Vanity Fair, 1/31/16
Bethany Mclean, Vanity Fair; Everything You Know About Martin Shkreli Is Wrong—or Is It? :
"I don’t mean to be presumptuous, but I liken myself to the robber barons.” So says Martin Shkreli, the 32-year-old hedge-fund manager turned pharmaceutical-company C.E.O., who achieved instantaneous notoriety last fall when he acquired the U.S. rights to a lifesaving drug and promptly boosted its price over 5,000 percent, from $13.50 a tablet to $750. The tsunami of rage (the BBC asked if Shkreli was “the most hated man in America”) only got worse when Shkreli said he would lower the price—and then didn’t. An anonymous user on the Web site Reddit summed up the sentiment bluntly: “Just fucking die will you?” “The attempt to public shame is interesting,” says Shkreli. “Because everything we’ve done is legal. [Standard Oil tycoon John D.] Rockefeller made no attempt to apologize as long as what he was doing was legal.” In fact, Shkreli says, he wishes he had raised the price higher. “My investors expect me to maximize profits,” he said in an interview in early December at the Forbes Healthcare Summit, after which Forbes contributor Dan Diamond summed up Shkreli as “fascinating, horrifying, and utterly compelling.”"
Subscribe to:
Posts (Atom)